Denos Health Management has launched Zionexa, a company established from proceeds of Denos' sale of Cyclopharma France that aims to improve patient care through breakthrough companion therapeutic and diagnostic radiotracers. Zionexa intends to begin the submission process to obtain FDA clearance for the PET tracer EstroTep, the EGFR protein-targeting IMAKinib tracer for lung cancer, and another fluorine-based radiopharmaceutical this summer.
New radiotracer firm unveiled by Denos Health Management
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.